References
- AsahchopELWainbergMASloanRDAntiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitorsAntimicrob Agents Chemother2012565000500822733071
- CohenCJMolinaJMCahnPEfficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE TrialsJ Acquir Immune Defic Syndr201260334222343174
- MolinaJMCahnPGrinsztejnBRilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trialLancet201137823824621763936
- CohenCJAndrade-VillanuevaJClotetBRilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trialLancet201137822923721763935
- CohenCMolinaJMCassettiIPooled week 96 efficacy, resistance and safety results from the double-blind, randomised, Phase III trials comparing rilpivirine (RPV, TMC278) versus efavirenz (EFV) in treatment-naive, HIV-1-infected adultsPresented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and PreventionRome, ItalyJuly 17–20, 2011
- CohenCMolinaJMCahnPPooled week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomized, Phase III trials comparing TMC278 versus efavirenz in treatment-naïve, HIV-1-infected patientsAbstract #TPOI-3 presented at the American Conference for the Treatment of HIVDenver, ColoradoApril 7–9, 2011
- HodderSArastehKDe WetJEffect of gender and race on the week 48 findings in treatment-naive, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVEHIV Med20121340641522416849
- MillsACohenCDe JesusESwitching from efavirenz-emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) single table regimen (STR) to emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) STR in virologically suppressed, HIV-1 infected subjectsPresented at the 51st Interscience Conference on Antimicrobial Agents and ChemotherapyChicago, ILSeptember 17–20, 2011
- CrauwelsHVingerhoetsJRyanRPharmacokinetic parameters of once-daily TMC278 following administration of efavirenz in healthy volunteersPresented at the 18th Conference on Retroviruses and Opportunistic InfectionsBoston, MAFebruary 27–March, 2011
- NelsonMAmayaGClumeckNEfficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trialsJ Antimicrob Chemother2012672020202822532465
- PozniakALMorales-RamirezJKatabiraEEfficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trialAIDS201024556519926964
- WilkinAPozniakALMorales-RamirezJLong-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trialAIDS Res Hum Retroviruses20122843744621902621
- DasKBaumanJDClarkADJrHigh-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutationsProc Natl Acad Sci USA20081051466147118230722
- AzijnHTirryIVingerhoetsJTMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1Antimicrob Agents Chemother20105471872719933797
- AsahchopELOliveiraMWainbergMACharacterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypesAntimicrob Agents Chemother20115560060721135184
- RimskyLVingerhoetsJVan EygenVGenotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysisJ Acquir Immune Defic Syndr201259394622067667
- PetrellaMWainbergMAMight the M184V substitution in HIV-1 RT confer clinical benefit?AIDS Rev2002422423212555696
- XuHTAsahchopELOliveiraMCompensation by the E138K mutation in HIV-1 reverse transcriptase of deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutationsJ Virol201185113001130821849444
- HuZKuritzkesDRInteraction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1J Virol201185113091131421849432
- KulkarniRBabaogluKLansdonEBThe HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitnessJ Acquir Immune Defic Syndr201259475421997204
- Edurant™ (prescribing information), Janssen. European Medicines Agency product information Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002264/WC500118874.pdfAccessed January 13, 2013
- Edurant™ (prescribing information). Tibotec Pharmaceuticals, full prescribing information label Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdfAccessed January 13, 2013
- CohenCGreenJOlivetHA randomized pilot study of tenofovir/ emtricitabine (TDF/FTC) boosted atazanavir (ATV/r) vs raltegravir (RAL BID) ATV/r vs RAL BID ATV BIDPresented at the Eleventh International Congress on Drug Therapy in HIV InfectionGlasgow, UKNovember 11–15, 2012
- FisherMPalellaFTebasPSPIRIT: switching to emtricitabine/rilpivirine/tenofovir DF single-tablet regimen from boosted protease inhibitor maintains HIV suppression at week 48Presented at the Eleventh International Congress on Drug Therapy in HIV InfectionGlasgow, UKNovember 11–15, 2012